Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-247.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -69.34% |
| Return on Assets (Trailing 12 Months) | -52.81% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.21 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 78.06M |
| Free Float | 74.00M |
| Market Capitalization | $431.65M |
| Average Volume (Last 20 Days) | 5.85M |
| Beta (Past 60 Months) | 0.67 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |